Aquestive Therapeutics, Inc. (AQST)
USD 3.0
(0.0%)
USD 3.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 74.95 Million USD | 160.06% |
| 2022 | 28.82 Million USD | 1.49% |
| 2021 | 28.39 Million USD | 227.49% |
| 2020 | 8.67 Million USD | -21.26% |
| 2019 | 11.01 Million USD | 182.2% |
| 2018 | -13.39 Million USD | -147.63% |
| 2017 | 28.12 Million USD | -4.46% |
| 2016 | 29.44 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 19.93 Million USD | -73.4% |
| 2024 Q2 | 27.01 Million USD | 35.51% |
| 2024 Q3 | -41.02 Million USD | -251.86% |
| 2023 Q3 | 20.12 Million USD | -11.3% |
| 2023 Q4 | 74.95 Million USD | 272.51% |
| 2023 FY | 74.95 Million USD | 160.06% |
| 2023 Q1 | 21.54 Million USD | -25.25% |
| 2023 Q2 | 22.68 Million USD | 5.3% |
| 2022 Q4 | 28.82 Million USD | -20.9% |
| 2022 Q3 | 36.43 Million USD | -4.84% |
| 2022 Q2 | 38.29 Million USD | -9.14% |
| 2022 FY | 28.82 Million USD | 1.49% |
| 2022 Q1 | 42.14 Million USD | 48.41% |
| 2021 Q4 | 28.39 Million USD | 131.26% |
| 2021 Q2 | 8.22 Million USD | -41.17% |
| 2021 Q3 | 12.27 Million USD | 49.31% |
| 2021 FY | 28.39 Million USD | 227.49% |
| 2021 Q1 | 13.98 Million USD | 61.23% |
| 2020 Q1 | 29.43 Million USD | 167.29% |
| 2020 FY | 8.67 Million USD | -21.26% |
| 2020 Q4 | 8.67 Million USD | -82.21% |
| 2020 Q3 | 48.74 Million USD | 21.82% |
| 2020 Q2 | 40.01 Million USD | 35.94% |
| 2019 Q4 | 11.01 Million USD | -71.66% |
| 2019 Q3 | 38.86 Million USD | 53.79% |
| 2019 Q2 | 25.26 Million USD | 229.97% |
| 2019 Q1 | 7.65 Million USD | 157.17% |
| 2019 FY | 11.01 Million USD | 182.2% |
| 2018 Q1 | 29.47 Million USD | 4.8% |
| 2018 FY | -13.39 Million USD | -147.63% |
| 2018 Q3 | -17.17 Million USD | -147.99% |
| 2018 Q4 | -13.39 Million USD | 22.02% |
| 2018 Q2 | 35.79 Million USD | 21.42% |
| 2017 FY | 28.12 Million USD | -4.46% |
| 2017 Q1 | 9.2 Million USD | 0.0% |
| 2017 Q4 | 28.12 Million USD | 0.0% |
| 2016 FY | 29.44 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 20.441% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 82.783% |
| Cosmos Health Inc. | 8.59 Million USD | -772.449% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 1012.525% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 83.66% |
| Cronos Group Inc. | -663.32 Million USD | 111.299% |
| Incannex Healthcare Limited | -5.48 Million USD | 1466.454% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 614.343% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 38.514% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 2683.211% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 579.384% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 579.384% |
| SCYNEXIS, Inc. | -19.35 Million USD | 487.339% |
| Safety Shot Inc | -2.28 Million USD | 3380.985% |
| Theratechnologies Inc. | 24.87 Million USD | -201.355% |
| Alpha Teknova, Inc. | 1.97 Million USD | -3696.859% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -37905.365% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 82.68% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 3074.206% |
| Dynavax Technologies Corporation | 106.63 Million USD | 29.714% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 87.977% |
| Radius Health, Inc. | 359.28 Million USD | 79.139% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 894.826% |
| Alvotech | 1.06 Billion USD | 92.958% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 157.289% |
| SIGA Technologies, Inc. | -148.68 Million USD | 150.41% |
| Shineco, Inc. | 29.29 Million USD | -155.887% |
| Silver Spike Investment Corp. | -32.61 Million USD | 329.826% |
| Journey Medical Corporation | -9.7 Million USD | 871.964% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 1581.113% |
| Embecta Corp. | 1.31 Billion USD | 94.287% |
| Harrow Health, Inc. | 116.41 Million USD | 35.619% |
| Procaps Group, S.A. | 242.93 Million USD | 69.148% |
| Biofrontera Inc. | 4.05 Million USD | -1747.88% |
| DURECT Corporation | -7.65 Million USD | 1079.227% |
| PainReform Ltd. | -7.95 Million USD | 1042.767% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 323.551% |
| OptiNose, Inc. | 58.06 Million USD | -29.079% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 1545.229% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -399.234% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -70039.155% |
| ProPhase Labs, Inc. | 19.23 Million USD | -289.735% |
| Phibro Animal Health Corporation | 454.84 Million USD | 83.522% |
| Procaps Group S.A. | 242.93 Million USD | 69.148% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -1937.792% |
| Viatris Inc. | 17.13 Billion USD | 99.562% |
| Rockwell Medical, Inc. | 4.45 Million USD | -1582.002% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 1636.805% |
| Tilray Brands, Inc. | 158.97 Million USD | 52.855% |
| PetIQ, Inc. | 351.93 Million USD | 78.703% |
| Talphera, Inc. | -5.72 Million USD | 1410.086% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 57.727% |
| Alimera Sciences, Inc. | 55.3 Million USD | -35.511% |
| Assertio Holdings, Inc. | -32.52 Million USD | 330.41% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 5134.52% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -1677.33% |
| Hempacco Co., Inc. | 13.61 Million USD | -450.509% |
| Alvotech | 1.06 Billion USD | 92.958% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 177.5% |
| Kamada Ltd. | -46.43 Million USD | 261.421% |
| Currenc Group, Inc. | -16.57 Million USD | 552.238% |
| Indivior PLC | -33.95 Million USD | 320.753% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -28663.422% |
| Flora Growth Corp. | -713 Thousand USD | 10611.921% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 1012.525% |
| Evolus, Inc. | 63.7 Million USD | -17.646% |
| HUTCHMED (China) Limited | -197.45 Million USD | 137.957% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 84.356% |
| Akanda Corp. | 3.9 Million USD | -1819.375% |